Safeguarding Patient Welfare: Who's In Charge?

@article{Henney2006SafeguardingPW,
  title={Safeguarding Patient Welfare: Who's In Charge?},
  author={J. Henney},
  journal={Annals of Internal Medicine},
  year={2006},
  volume={145},
  pages={305-307}
}
  • J. Henney
  • Published 2006
  • Medicine
  • Annals of Internal Medicine
  • Over the course of my career, I have been privileged to serve in a variety of roles, including that of oncologist, principal investigator, study manager, senior academic administrator, Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA), and as board member for 3 Fortune 500 and Global 500 companies (AstraZeneca PLC, 2001 to present; AmerisourceBergen Corporation, 2002 to present; and Cigna Corporation, 2004 to present). I have been regulated and a regulator, and I… CONTINUE READING
    8 Citations
    Evaluating Off-Label Uses of Anticancer Drugs: Time for a Change
    • H. Sox
    • Medicine
    • Annals of Internal Medicine
    • 2009
    • 13
    Sorrell v. IMS Health: issues and opportunities for informaticians
    • 5
    • PDF
    Who needs another journal?
    Pharmaceutical promotion to physicians and First Amendment rights.
    • 30
    • PDF
    Indication creep: physician beware
    • 22
    • PDF
    L'expansion des indications : médecins, attention
    • 2
    • PDF

    References

    SHOWING 1-6 OF 6 REFERENCES
    Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
    • 284
    • Highly Influential
    • PDF
    Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
    • 48
    • PDF
    Off-label prescribing among office-based physicians.
    • 581
    • PDF
    New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
    • 40
    • PDF
    Shalala, 130 F.Supp
    • (D. DC
    • 2001
    Advertising and Promotion
    • 381